| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/02/2011 | EP2289507A1 Pharmaceutical compositions of CETP inhibitors |
| 03/02/2011 | EP2289506A2 Medicament comprising a C11-C21 alkanoic, alkenoic or alkynoic acid ester and a catechin |
| 03/02/2011 | EP2289505A1 Nutritional composition and food supplement containing such a nutritional composition. |
| 03/02/2011 | EP2289504A2 SIRT1 modulators for manipulating cell/organism lifespan/stress response |
| 03/02/2011 | EP2289503A2 Treating muscle wasting with selective androgen receptor modulators |
| 03/02/2011 | EP2289502A1 Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor |
| 03/02/2011 | EP2289501A1 Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor |
| 03/02/2011 | EP2289500A1 Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension |
| 03/02/2011 | EP2289499A2 Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
| 03/02/2011 | EP2289498A1 Use of inhibitors of glutaminyl clyclase |
| 03/02/2011 | EP2289497A1 Once-daily administration of central nervous system drugs |
| 03/02/2011 | EP2289493A1 Solid naproxen concentrates and related dosage forms |
| 03/02/2011 | EP2289492A2 Naltrexone hydrochloride compositions |
| 03/02/2011 | EP2289489A2 Compositions comprising cyclohexylamines and aminoadamantanes |
| 03/02/2011 | EP2289488A2 Remedies for diseases to be applied to eye |
| 03/02/2011 | EP2289343A1 Flavanones-containing food compositions |
| 03/02/2011 | EP2288923A2 Compositions and methods of treatment using modulators of motoneuron diseases |
| 03/02/2011 | EP2288704A2 Enhancement of drug therapy by mirna |
| 03/02/2011 | EP2288702A1 Combination therapies against cancer |
| 03/02/2011 | EP2288629A1 Biosourced acrolein polymer, method for obtaining same, and uses thereof |
| 03/02/2011 | EP2288615A1 Selective caspase inhibitors and uses thereof |
| 03/02/2011 | EP2288613A1 Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
| 03/02/2011 | EP2288612A1 Gabaa receptor modulators |
| 03/02/2011 | EP2288611A1 Aurora kinase modulators and method of use |
| 03/02/2011 | EP2288610A1 Azetidine and cyclobutane derivatives as jak inhibitors |
| 03/02/2011 | EP2288608A1 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use |
| 03/02/2011 | EP2288607A1 Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| 03/02/2011 | EP2288606A1 New co-crystal compound of rivaroxaban and malonic acid |
| 03/02/2011 | EP2288605A1 Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| 03/02/2011 | EP2288604A1 Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| 03/02/2011 | EP2288602A1 Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
| 03/02/2011 | EP2288601A1 Bicyclylaryl-aryl-amine compounds and their use |
| 03/02/2011 | EP2288600A1 Substituted arylcyclopentenes as prostaglandin ep2 agonists |
| 03/02/2011 | EP2288598A1 Thiophene derivatives useful as ocular hypotensive agents |
| 03/02/2011 | EP2288596A2 Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use |
| 03/02/2011 | EP2288594A1 Imidazolidine derivatives |
| 03/02/2011 | EP2288414A1 Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid |
| 03/02/2011 | EP2288383A1 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| 03/02/2011 | EP2288378A1 Pharmacological targeting of vascular malformations |
| 03/02/2011 | EP2288364A1 Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
| 03/02/2011 | EP2288356A1 Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation |
| 03/02/2011 | EP2288355A1 Method and composition for skin inflammation and discoloration |
| 03/02/2011 | EP2288354A1 Substituted benzimidazoles for neurofibromatosis |
| 03/02/2011 | EP2288353A2 Method for treating acute pain with a formulated drug depot in combination with a liquid formulation |
| 03/02/2011 | EP2288352A2 Clonidine formulation in a polyorthoester carrier |
| 03/02/2011 | EP2288351A2 Novel pyrrolidone derivatives for use as metap-2 inhibitors |
| 03/02/2011 | EP2288350A1 Method of treatment with potentised stereoisomer of glutamate |
| 03/02/2011 | EP2288349A1 Therapy regimen for treating acne related diseases |
| 03/02/2011 | EP2288348A1 Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
| 03/02/2011 | EP2288347A1 Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients |
| 03/02/2011 | EP2288346A1 Oral compositions containing enhanced antibacterial combinations of antioxidants and extracts of magnolia |
| 03/02/2011 | EP2288345A1 Psycho-pharmaceuticals |
| 03/02/2011 | EP2288344A1 A transdermal drug delivery device |
| 03/02/2011 | EP2288340A1 Nanoparticle formulations and uses thereof |
| 03/02/2011 | EP2288335A1 Process for preparing orally administered dabigatran formulations |
| 03/02/2011 | EP2288334A1 Composition and method for transmucosal delivery of lofexidine |
| 03/02/2011 | EP2288260A1 Triazolopyridine jak inhibitor compounds and methods |
| 03/02/2011 | EP2288259A2 Stabilized, antimicrobially effective composition with a content of bispyridinium alkane |
| 03/02/2011 | EP2190834B1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 03/02/2011 | EP2178511B1 Tableted compositions containing atazanavir |
| 03/02/2011 | EP2137181B1 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists |
| 03/02/2011 | EP2097423B1 Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production |
| 03/02/2011 | EP2086969B1 3-cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases |
| 03/02/2011 | EP2081904B1 Aripiprazole hemifumarate and process for its preparation |
| 03/02/2011 | EP2069332B1 Azetidine compounds as orexin receptor antagonists |
| 03/02/2011 | EP2066685B1 Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
| 03/02/2011 | EP2046748B1 Phenylpentadienoyl derivatives and their use as par 1 antagonists |
| 03/02/2011 | EP2040712B1 Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| 03/02/2011 | EP2035417B1 Benzimidazoles and their use for the treatemnt of diabetes |
| 03/02/2011 | EP2004601B1 Novel dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical compositions containing them |
| 03/02/2011 | EP1966146B1 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators |
| 03/02/2011 | EP1957481B1 Pyrrolidin(thi)ones heterocyclically substituted in 3-position |
| 03/02/2011 | EP1957479B1 1,5-substituted indol-2-yl amide derivatives |
| 03/02/2011 | EP1915365B1 Carboxamide compound and use of the same |
| 03/02/2011 | EP1904432B1 Oligomers of straight-chain and unbranched fatty acids, and medicaments containing the same |
| 03/02/2011 | EP1901731B1 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 03/02/2011 | EP1884236B1 Angiogenesis inhibitor containing amine derivative as active ingredient |
| 03/02/2011 | EP1836176B1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEROF |
| 03/02/2011 | EP1831174B1 Amide derivatives |
| 03/02/2011 | EP1830827B1 Perfluorocarbon liquids to remove carcinogens |
| 03/02/2011 | EP1827452B1 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol |
| 03/02/2011 | EP1814871B1 Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 03/02/2011 | EP1814848B9 2,3,4-substituted-cyclopentanones as therapeutic agents |
| 03/02/2011 | EP1773332B1 Pharmaceutical composition for the treatment of bone fracture |
| 03/02/2011 | EP1704148B1 Novel fused pyrrolocarbazoles |
| 03/02/2011 | EP1694654B1 Substituted triazoles as sodium channel blockers |
| 03/02/2011 | EP1686951B1 Combined cosmetic or therapeutic preparation |
| 03/02/2011 | EP1668011B1 Hiv replication inhibiting purine derivatives |
| 03/02/2011 | EP1656131B1 Use of betaine for treating intermittent claudication |
| 03/02/2011 | EP1638552B1 Use of (3.2.0) heterocyclic compounds and analogs thereof for the treatment of cancer |
| 03/02/2011 | EP1585732B1 Spermicidal composition and methods of using the same |
| 03/02/2011 | EP1581518B1 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 03/02/2011 | EP1578715B1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 03/02/2011 | EP1513934B1 Genes and polypeptides relating to human colon cancers |
| 03/02/2011 | EP1513846B1 Process of preparation of olanzapine form i |
| 03/02/2011 | EP1511489B1 New pharmaceutical compositions containing flibanserin polymorph a |
| 03/02/2011 | EP1436403B1 Use of the adenoviral e2 late promoter |
| 03/02/2011 | EP1417975B1 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| 03/02/2011 | EP1389102B1 Use of lanthanum carbonate for the prevention of kidney stone disease |
| 03/02/2011 | EP1383761B1 Phenyl- and pyridyl-piperidines with tnf activity |